State Street SPDR S&P 500 ETF (SPY) vs Vertex Pharmaceuticals Incorporated (VRTX)
Over the past 10 years, VRTX outperformed SPY — 18.72% vs 15.36% annualized total return (price plus dividends).
A side-by-side comparison of State Street SPDR S&P 500 ETF and Vertex Pharmaceuticals Incorporated across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of September 10, 2026. Differences are shown without an overall score or investment verdict.
Total return — SPY vs VRTX
growth of $100 · dividends reinvested · last 10yMetrics side by side
Did VRTX beat SPY?
Over the past 10 years, VRTX outperformed SPY — 18.72% vs 15.36% annualized total return (price plus dividends).
Total return (annualized)
| Metric | SPY | VRTX |
|---|---|---|
| Total return (1Y) | 17.49% | 31.46% |
| Total return CAGR (3Y) | 20.82% | 14.94% |
| Total return CAGR (5Y) | 12.73% | 22.61% |
| Total return CAGR (10Y) | 15.36% | 18.72% |
SPY is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).
Frequently asked
- Has VRTX beaten SPY?
- Over the past 10 years, VRTX outperformed SPY — 18.72% vs 15.36% annualized total return (price plus dividends).
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified September 10, 2026.